TLGS service · E5
Regulatory and data-governance advisory for healthcare aggregators and technology platforms working with public-sector institutions.
Advisory coverage
Our work · Institutional client
TLGS is a long-standing pan-India regulatory advisory and operational-compliance partner to Tata 1mg, supporting defined assignments across retail pharmacy, e-pharmacy, institutional healthcare and e-diagnostics.
Explore the engagement →TLGS expertise
Former Senior Director, Tata Consultancy ServicesIndependent-director and Risk Management Committee chair experience, Dr Lal PathLabs
Director & Practice Chair
Corporate Governance, Risk, Digital Strategy & Board Advisory
Board and strategy professional with experience in corporate governance, risk oversight, technology commercialisation and healthcare.
View profileFormer Judge
Director & Group Principal
Collaborations & Strategic Growth
Former Judge with multidisciplinary experience across international trade, infrastructure and EPC, public procurement, regulatory strategy and enterprise growth. Leads TLGS’s collaborations and strategic-growth remit.
View profileBoard Affairs & Strategic Communication Lead
MD Office
Company Secretary with experience in corporate law, board affairs, FEMA, secretarial compliance and strategic communication.
View profileRegional Lead
UAE & Middle East Business Operations
Consulting and business-analysis professional with experience in healthcare initiatives, MSME policy, technology and cross-border coordination.
View profileBharat Pulse · Healthcare regulatory insights
Dated regulatory notes with official references and a separately identified TLGS perspective.
A Maharashtra FDA order brings prescription access and patient choice into the operating controls of hospital-linked pharmacy services.
Official order · reviewed 13 September 2026
Read the sourced insight →Current Maharashtra FDA portal guidance makes application-channel verification an important first step for new manufacturing and sales users.
Official portal guidance · reviewed 13 September 2026
Read the sourced insight →A central-government reply explains the public drug-alert process. For retail and e-pharmacy networks, the operating question is how an alert becomes a traceable, location-specific response.
Official parliamentary reply · reviewed 13 September 2026
Read the sourced insight →These are independent TLGS sector notes, not Tata 1mg statements or findings about a client. Review dates are not announcement dates.
The scope of each engagement is agreed after review of the facts, documents, applicable framework and conflicts. Services are advisory and coordination-led; court appearances, reserved professional work and technical certifications are undertaken through appropriately authorised professionals. No court, regulatory, funding or commercial outcome is guaranteed.
This capability in practice
Strategic advisory connecting a digital-health enterprise’s consumer, corporate and institutional channels with partnership design, governance and regulatory positioning.
Market-development & institutional structuringChallenge, solution & delivery →